PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Ji-Hoon | - |
dc.contributor.author | Kim, Keun Pil | - |
dc.contributor.author | Ko, Jeong-Jae | - |
dc.contributor.author | Park, Kyung-Soon | - |
dc.date.available | 2019-03-08T12:38:20Z | - |
dc.date.issued | 2016-08 | - |
dc.identifier.issn | 0006-291X | - |
dc.identifier.issn | 1090-2104 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/6633 | - |
dc.description.abstract | Drug resistance in breast cancer remains a major obstacle of clinical therapy. We found that suppression of ELK3 in the triple negative breast cancer cell line MDA-MB-231 impaired autophagy and led to a hypersensitive response to doxorubicin treatment. In ELK3-knockdown MDA-MB-231 cells (ELK3 KD), autophagy was not activated under starvation conditions, which is a major stimulus of autophagy activation. We revealed that activation of the PI3K/Akt pathway was the main cause of impaired autophagy in ELK3 KD. Our results suggest that targeting ELK3 may be a potential approach to overcome doxorubicin resistance in breast cancer therapeutics. (C) 2016 Published by Elsevier Inc. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE | - |
dc.title | PI3K/Akt/mTOR activation by suppression of ELK3 mediates chemosensitivity of MDA-MB-231 cells to doxorubicin by inhibiting autophagy | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.bbrc.2016.06.057 | - |
dc.identifier.bibliographicCitation | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, v.477, no.2, pp 277 - 282 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000381166000020 | - |
dc.identifier.scopusid | 2-s2.0-84976609228 | - |
dc.citation.endPage | 282 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 277 | - |
dc.citation.title | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | - |
dc.citation.volume | 477 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Autophagy | - |
dc.subject.keywordAuthor | Doxorubicin | - |
dc.subject.keywordAuthor | ELK3 | - |
dc.subject.keywordAuthor | MDA-MB-231 cell line | - |
dc.subject.keywordAuthor | PI3K/Akt | - |
dc.subject.keywordPlus | ADVANCED SOLID TUMORS | - |
dc.subject.keywordPlus | BREAST-CANCER CELLS | - |
dc.subject.keywordPlus | PHASE-I TRIAL | - |
dc.subject.keywordPlus | HYDROXYCHLOROQUINE | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.subject.keywordPlus | KINASE | - |
dc.subject.keywordPlus | NET | - |
dc.subject.keywordPlus | TRANSCRIPTION | - |
dc.subject.keywordPlus | TEMOZOLOMIDE | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biophysics | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biophysics | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.